Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Evaluation of a conjugate of purified antibodies against human AFP-dextran-daunorubicin to human AFP-producing yolk sac tumor cell lines

  • 21 Accesses

  • 12 Citations

Summary

The anticancer drug, DNR, was conjugated to an affinity-purified horse antibody to human AFP (aAFP) via a dextran bridge. The conjugate (immunoglobulin: DNR molar ratio, 1:50) was twice as potent as free DNR in an in vitro cytotoxicity assay against an AFP-producing human yolk sac tumor. The in vivo effect of aAFP, DNR, and the conjugate was tested against the human yolk sac tumor growing in nude mice. The conjugate, at a concentration of DNR containing the equivalent amount of 20 μg or 70 μg/mouse significantly retarded tumor growth whereas free aAFP showed only a slight inhibition of tumor growth compared to the PBS-treated control. Mice which received 20 μg/mouse of free DNR showed a moderate retardation of tumor growth whereas those which received 70 μg/mouse of DNR or a mixture of DNR and aAFP showed emaciation and early death due to acute toxicity of the drug. These results suggest that the anti-body-drug conjugate accumulated preferentially on the AFP-producing tumor cells and that cytotoxicity occurred.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Embleton MJ, Rouland GF, Simmonds RG, Jacobs E, Marsden CH, Baldwin RW (1983) Selective cytotoxicity against human tumour cells by a vindesine-monoclonal antibody conjugate. Br J Cancer 47:43–49

  2. 2.

    Ganett MC, Embleton, MJ, Jacobs E, Baldwin, RE (1983) Preparation and properties of a drug-carrier-antibody conjugate showing selective antibody-directed cytotoxicity in vitro. Int J Cancer 31:661–670

  3. 3.

    Hurwitz E, Levy R, Maron R, Wilchek M, Arron R, Sela M (1975) The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities. Cancer Res 35:1175–1181

  4. 4.

    Mizejewski GJ, Allen RP (1974) Immunotherapeutic suppression in transplantable solid tumours. Nature 250:50–51

  5. 5.

    Mizejewski GJ, Young SR, Allen RP (1975) Alpha-fetoprotein: Effect of heterologous antiserum on hepatoma in vitro. J Natl Cancer Inst 54:1361–1367

  6. 6.

    Motoyama T, Hujo H, Suzuki T, Oboshi S (1979) Evaluation of the regrowth assay method as an in vitro drug sensitivity test and its application to cultured human gastric cancer cell lines. Acta Med Biol 27:49–63

  7. 7.

    Nishi S, Hirai H (1972) Purification of human, dog and rabbit α-fetoprotein by immunoadsorbents of sepharose coupled with anti-human α-fetoprotein. Biochim Biophys Acta 278:293–298

  8. 8.

    Nishi S, Nishita T, Hirai H (1982) Human yolk sac tumor produced 13 serum proteins. Abstracts of 10th Annual Meeting of the International Society for Oncodevelopmental Biology and Medicine, A119

  9. 9.

    Ohkawa K, Koike K, Amasaki H, Tohtake T, Nakata H, Dohsono H (1980) Heterotransplantation of human embryonal carcinoma into the nude mice, functional and morphologic examination. Asia Oceania J Obstet Gynaecol 6:73–81

  10. 10.

    Ohkawa K, Tsukada Y, Hibi N, Hirai H (1984) The inhibitory effects of horse anti-rat AFP antiserum on the uptake of 2-deoxy-D-glucose by AFP-producing rat hepatoma cells. Int J Cancer 33:497–502

  11. 11.

    Okabe T, Suzuki A, Ohsawa N, Kosaka K, Terashima T (1979) Immune elimination of host fibroblasts for the cultivation of human tumors transplanted into nude mice. Cancer Res 39:4189–4194

  12. 12.

    Povlsen CO, Jacobsen GK (1975) Chemotherapy of a human malignant melanoma transplanted in the nude mouse. Cancer Res 35:2790–2796

  13. 13.

    Rowland GF, Axton CA, Baldwin RW, Brown JP, Corvalan JR, Embleton MJ, Gore VA, Hellström I, Hellström KE, Jacobs E, Marsden CH, Pimm MV, Simmonds RG, Smith W (1985) Antitumor properties of vindesine-monoclonal antibody conjugates. Cancer Immunol Immunother 19:1–7

  14. 14.

    Rygaard J, Povlsen CO (1969) Heterotransplantation of a human malignant tumour to “nude” mice. Acta Pathol Microbiol Scand 77:758–760

  15. 15.

    Sawada M, Matusi Y, Okudaira Y (1983) Chemotherapy of human yolk sac tumor heterotransplanted in nude mice. J Natl Cancer Inst 71:1221–1225

  16. 16.

    Steel GG, Courtenay VD, Peckham MJ (1983) The response to chemotherapy of a variety of human tumor xenografts. Br J Cancer 47:1–13

  17. 17.

    Taketa K, Izumi M, Ichikawa E (1983) Distinct molecular species of human α-fetoprotein due to differential affinities to lectins. Annal NY Acad Sci 417:61–68

  18. 18.

    Tsukada Y, Mikuni M, Watabe H, Nishi S, Hirai H (1974) Effects of anti-α-fetoprotein serum on some cultured tumor cells. Int J Cancer 13:187–195

  19. 19.

    Tsukada Y, Bishof WKD, Hibi N, Hirai H, Hurwitz E, Sela M (1982) Effect of a conjugate of daunomycin and antibodies to rat α-fetoprotein on the growth of α-fetoprotein-producing tumor cells. Proc Natl Acad Sci USA 79:621–625

  20. 20.

    Tsukada Y, Hurwitz E, Kashi R, Sela M, Hibi N, Hara A, Hirai H (1982) Chemotherapy by intravenous administration of conjugates of daunomycin with monoclonal and conventional anti-rat-α-fetoprotein antibodies. Proc Natl Acad Sci USA 79:7896–7899

  21. 21.

    Tsukada Y, Kato Y, Umemoto N, Takeda Y, Hara T, Hirai H (1984) An anti-α-fetoprotein antibody-daunoroubicin conjugate with a novel poly-L-glutamic acid derivative as intermediate drug carrier. J Natl Cancer Inst 73:721–729

  22. 22.

    Tsukada Y, Ohkawa K, Hibi N (1985) Suppression of human α-fetoprotein-producing hepatocellular carcinoma growth in nude mice by an anti α-fetoprotein antibody-daunorubicin conjugate with a poly-L-glutamic acid derivative as intermediate drug carrier. Br J Cancer 52:111–116

  23. 23.

    Wepsic HT, Tsukada Y, Takeichi N, Nishi S, Hirai H (1980) Effect of horse antibody to rat alpha-fetoprotein upon the growth of AH66 in Donryu rats. Int J Cancer 25:655–661

Download references

Author information

Correspondence to Yutaka Tsukada.

Additional information

Abbreviations used: AFP=alpha-fetoprotein; aAFP=purified antibodies to human AFP; dex=dextran; DNR=daunorubicin; PBS=Ca2+−Mg2+-free Dulbecco's phosphate-buffered saline RV=relative tumor volume; T/C=percent ratio of RV for treated mice to RV for control

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ohkawa, K., Hibi, N. & Tsukada, Y. Evaluation of a conjugate of purified antibodies against human AFP-dextran-daunorubicin to human AFP-producing yolk sac tumor cell lines. Cancer Immunol Immunother 22, 81–86 (1986). https://doi.org/10.1007/BF00199119

Download citation

Keywords

  • Tumor Growth
  • Dextran
  • Nude Mouse
  • Anticancer Drug
  • Tumor Cell Line